Author: chee

OSAKA, Japan, Feb 5, 2026 - (ACN Newswire via SeaPRwire.com) – February 4, 2026, SuperX Industries Co., Ltd. ("SuperX"), a Japanese subsidiary of SuperX AI Technology Limited (“NASDAQ:SUPX”), today announced the signing of an Memorandum of Understanding ("MOU") on February 4, 2026 with Digital Dynamic Inc. ("DD"), eole Inc. ("eole"), and Woodman Inc. ("Woodman"). This MOU builds on the parties’ prior cooperation to establish a comprehensive framework for the co-development of large-scale AI Data Centers (AIDC) across Japan.Advancing the Mie Prefecture Pilot ProjectFollowing the first MOU signed on January 30, 2026 in Osaka, Japan, the Parties entered into the MOU to further deepen collaboration by establishing a joint task force to pilot an AIDC project in Mie Prefecture, Japan with an initial facility capacity up to 4MW, subject to feasibility assessments, site conditions, regulatory approvals, and the execution of definitive agreements. The pilot initiative is intended to serve as a starting point for assessing potential future expansion up to 300MW in total capacity.Addressing Japan’s AI Infrastructure BottleneckThe shift toward modular architecture directly addresses Japan’s growing demand for the expansion of domestic AI capacity on an accelerated timeline. Unlike traditional "brick-and-mortar" builds that can take years to complete, SuperX’s modular approach accelerates deployment by reducing construction timelines significantly. This new pilot project is designed to be purpose-built for next-generation, liquid-cooled GPUs—capabilities often lacking in legacy data centers.Scalable delivery and reliable operationsPursuant to the MOU, the Parties intend to collaborate on the system-level integration of critical infrastructure, including advanced power systems and liquid cooling solutions essential for continuous AI workloads. The framework also contemplates the future integration of renewable energy components, such as solar and wind power, energy storage systems, and grid interconnection, subject to site conditions, commercial viability and regulatory approvals.To facilitate execution, a joint task force is expected to be established to define technical architecture, governance, and near-term milestones. SuperX will lead the provision of the modular system architecture and power system integration.Executive quote“Speed-to-market is the new currency in the AI race,” said Aiko Furukawa, the CEO of SuperX Industries Co. Limited. “This pilot project in Mie Prefecture is intended to demonstrate how we can deploy AI infrastructure with speed. Alongside our partners, we aim to demonstrate that modular scalability is the most viable path to meeting Japan's surging demand for AI.”Looking aheadLooking forward, the Parties intend to use the initial pilot as a reference framework to evaluate broader modular AIDC opportunities across Japan, including scalable pathways for expansion—subject to further feasibility assessments, regulatory approvals, site conditions, and the negotiation and execution of definitive agreements.About Digital Dynamic IncDigital Dynamic Inc. is one of Japan’s fastest-growing AI infrastructure operators, with a rapidly expanding deployment of NVIDIA-based inference GPU resources. In 2026, the company plans to complete AI data centers in Kagoshima Prefecture and Fukushima Prefecture, reinforcing Japan’s next-generation AI computing foundation.About eole Inceole Inc. is a publicly listed company in Japan with a rapidly growing presence in the domestic GPU server market. The company provides investment and business development support for AI data center development projects, playing an active role in advancing Japan’s AI infrastructure ecosystem.About Woodman IncWOODMAN Inc. is a Japanese technology company focusing on eliminating societal waste by transforming underutilized resources, such as surplus electricity and computing power, into new value. They specialize in constructing optimized computing environments for AI and HPC (High-Performance Computing), bridging the gap between energy infrastructure and, previously, blockchain/mining hardware.About SuperX AI Technology Limited (NASDAQ:SUPX)SuperX AI Technology Limited is an AI infrastructure solutions provider, offering a comprehensive portfolio of proprietary hardware, advanced software, and end-to-end services for AI data centers. The Company's services include advanced solution design and planning, cost-effective infrastructure product integration, and end-to-end operations and maintenance. Its core products include high-performance AI servers, 800 Volts Direct Current (800VDC) solutions, high-density liquid cooling solutions, as well as AI cloud and AI agents. Headquartered in Singapore, the Company serves institutional clients globally, including enterprises, research institutions, and cloud and edge computing deployments. For more information, please visit www.superx.sgSafe Harbor Statement This press release may contain forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement.Forward-looking statements are only predictions. The reader is cautioned not to rely on these forward-looking statements. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Shanghai, January 5, 2026 - (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive license agreement with Shaanxi Micot Pharmaceutical Technology Co., Ltd. (“Micot”) to commercialize MT1013, the world’s first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor and is primarily developed with Secondary Hyperparathyroidism (SHPT) as its leading indication, in China and Asia-Pacific (excluding Japan).According to the agreement, Everest Medicines will pay Micot an upfront payment of RMB 200 million and potential regulatory and commercial milestone payments of up to RMB 1,040 million. MT1013 has entered Phase III clinical trial in China and the relevant development expenses will be covered by Micot. The strategic collaboration is expected to complement Everest Medicines’ existing renal pipeline and drive operating synergies, further strengthen the Company’s commercial product portfolio, and solidify its leading position in renal and autoimmune diseases in Asia, which are key therapeutic areas of focus. The collaboration will also expand the Company’s nephrology portfolio from IgA nephropathy to a broader range of chronic kidney diseases (CKD).MT1013 is the world’s first-in-class dual-targeting receptor agonist polypeptide internally developed by Micot. The Phase II data were presented orally and in a Late-Breaking session at the 2025 American Society of Nephrology (ASN) Annual Meeting. MT1013 uniquely combines the calcium-sensing receptor (CaSR) and the osteogenic growth peptide (OGP) receptor, addressing imbalances in parathyroid hormone (PTH), calcium, and phosphate metabolism. This innovative dual mechanism allows MT1013 to control SHPT and related bone metabolism disorders at the source, and to actively promote bone formation and repair through direct activation of osteogenic pathways, representing a therapeutic innovation shift from indirect inhibition of bone resorption to active stimulation of bone formation.Clinical studies have demonstrated that MT1013 acts rapidly, with strong and durable efficacy, and has a favorable safety profile in patients with CKD on maintenance hemodialysis with SHPT. It has shown potential advantages over current therapies in achieving comprehensive endpoints, including control of intact parathyroid hormone (iPTH), serum calcium, and phosphate levels, as well as improving calcium-phosphate balance and offering potential cardiovascular benefits. MT1013 is currently being evaluated in a Phase III clinical trial in China for this patient population, with over 50% of the target enrollment already achieved. SHPT is one of the most common and serious complications in patients with CKD. It causes disturbances in calcium and phosphate metabolism, elevated PTH levels, bone disorders, and vascular calcification, which substantially increase the risk of fractures, cardiovascular events, and mortality. SHPT is therefore an important factor influencing outcomes and prognosis in patients with CKD. With the global prevalence of CKD continuing to rise, the unmet medical need for effective SHPT therapies is also growing. Data indicate that the global population of patients with CKD has increased from 905.2 million in 2019 to 1.0655 billion in 2024 and is projected to exceed 1.2 billion by 2030 and 1.5 billion by 2035. Over the same period, the number of patients with SHPT has also continued to rise and is expected to reach approximately 189.9 million by 2030 and 221.7 million by 2035, highlighting a substantial and growing unmet medical need.“We are very pleased to collaborate with Micot. As the global burden of chronic kidney disease continues to rise, addressing patients’ unmet needs remains a top priority.,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “MT1013 represents an innovative asset with the potential to expand treatment options for patients with secondary hyperparathyroidism. Through this partnership, we aim to leverage our expertise in autoimmune-related kidney disorders while broadening our renal portfolio to include additional diseases, including glomerulonephritis and complications associated with dialysis. Looking ahead, we will jointly advance the development and commercialization of MT1013 to bring innovative treatment options to a broader population of patients with kidney disease.”“We are delighted to enter into this strategic collaboration with Everest Medicines. Everest’s deep expertise in nephrology and established commercialization capabilities make it an ideal partner to bring MT1013 to patients in China and beyond,” said Dr. Bing Wang, Founder, Chairman, and President of Micot. “MT1013 is a pivotal achievement of our peptide technology platform and a key milestone in our commitment to advancing innovative therapies for chronic diseases. Its unique dual-targeting mechanism has the potential to deliver meaningful advances in the treatment of secondary hyperparathyroidism. We look forward to working closely with Everest to accelerate clinical development and commercialization, address critical unmet medical needs, and advance care for patients with kidney disease.”MT1013 has completed its pivotal Phase II clinical trial, which demonstrated robust and sustained iPTH suppression in patients with SHPT undergoing maintenance hemodialysis. In head-to-head comparisons with etelcalcetide, MT1013 showed advantages in comprehensive disease management, achieving higher rates of simultaneous control of iPTH, serum calcium, and phosphate, as well as greater reductions in phosphate and the cardiovascular risk marker FGF-23. Over 52 weeks of treatment, MT1013 also resulted in significant improvements in bone mineral density and bone metabolism markers, supporting the potential clinical benefits of its unique dual-target mechanism in both disease management and bone health.Building on these positive results, the Phase II data were presented orally and in a Late-Breaking session at the 2025 American Society of Nephrology Annual Meeting. MT1013 has now advanced into a confirmatory Phase III clinical trial in China with cinacalcet as the active comparator. The Phase III study has been launched across more than 100 sites nationwide, aiming to enroll approximately 424 patients, specifically targeting individuals with SHPT undergoing maintenance hemodialysis due to chronic kidney disease.About MT1013MT1013 is the world’s first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor and is primarily developed with Secondary Hyperparathyroidism as its leading indication and is planned to expand into additional indications including Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) with Osteoporosis and SHPT not on Dialysis. MT1013 completed its Phase II clinical trial (MT1013-II-C01) for the treatment of SHPT in May 2025 and has entered a Phase III clinical trial using Cinacalcet as the active comparator.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.The Company’s therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company’s website: www.everestmedicines.com.About MicotShaanxi Micot Pharmaceutical TechnologyCo., Ltd.("Micot") was founded in Xi’an in January 2007 and now operates in China (Xi’an, Suzhou, Beijing, Shanghai, Hong Kong) and the U.S. An R&D-driven innovator, Micot develops dual- and multi-functional peptide drugs for cardiovascular/cerebrovascular and metabolic diseases to address unmet clinical needs.As the proposer, implementer, validator, and developer of the bispecific peptide concept, Micot stands as a premier platform for peptide drug R&D. It utilizes a unique mechanism for screening multi-target peptide therapeutics and possesses platform-based R&D capabilities to develop both First-in-class and Best-in-class candidates.Currently, Micot has a robust reserve of new drug candidates, with seven proprietary innovative pipelines currently in clinical stage: one in Phase III, three in Phase II, and three in Phase I. Dedicated to creating breakthrough medicines and saving lives, Micot strives to address unmet clinical needs and leverages scientific innovation to safeguard human health. For more information, please visit the website: www.micot.cn.Forward-Looking StatementsThis news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - February 4, 2026) - Military Metals Corp. (CSE: MILI) (OTCQB: MILIF) (FSE: QN90) (the "Company" or "MILI") is pleased to report the additional analytical results of the Company's definition drilling campaign at the 100% owned flagship Trojárová Antimony-Gold Project (the "Project") in Slovakia as announced on November 4, 2025. The 2025 drilling campaign was designed to confirm historical drilling results and to support SLR Consulting's work towards establishing a current mineral resource estimate on the Project, which the company anticipates delivery of by the end of Q1, 2026, further discussed in the Company's January 9, 2025 announcement.These priority assay results represent the main mineralized zone from the third hole of the program, 25-TVA-003.Highlights of the Results from hole 25-TVA-003 Include:23.5 drilled (m) of 3.3 g/t Gold over a true width of 20.2m from 148.9m to 172.4mIncluding: 4.0m of 10.52 g/t Au over a true width of 3.4m from 157.9m to 161.9m1.9m of 2.53% Antimony over a true width of 1.6m from 169.9m to 171.8mScott Eldridge, Chief Executive Officer of the Company, commented, "We are thrilled with the second tranche of assays as we continue to see antimony grades that are consistent with historical results and higher than anticipated gold grades within the Trojárová Deposit. These strong gold results present the Company with new exploration opportunities that we are excited to evaluate. Trojárová represents the only antimony deposit in the European Union being advanced by modern mineral exploration and demonstrates characteristics that place it among the leading antimony projects globally. At a time when the need for secure, domestically sourced critical minerals is more pressing than ever, these results strengthen the project's potential importance to, and alignment with, the EU's objective of building a dependable, home-grown supply of essential raw materials."The Company additionally announces that logging and sampling of all drill core from the program is complete and all samples have successfully been delivered to ALS Laboratories in Roșia Montană, Romania for analysis. Additional results for all holes are pending.Table 1. Complete table of analytical results discussed in this release. Results exceeding 1.0 % Sb or 1.0 g/t Au are highlighted in red.Hole IDFrom (m)To (m)Drilledlength (m)True Width (m)Sample IDAntimony %Gold g/t25-TVA-003145.55146.50.950.813256260.016 0.01 146.5147.10.60.513256270.093 0.04 147.1148.110.863256280.123 0.52 148.1148.90.80.693256290.116 0.38 148.9149.910.863256311.145 1.1220.15m @ 3.3g/t True Width 149.9150.910.863256320.244 0.75 150.9151.910.863256330.057 0.7 151.9152.910.863256340.057 3.74 152.9153.910.863256360.279 4.5 153.9154.910.863256370.031 0.81 154.9155.910.863256380.189 1.05 155.9156.910.863256390.96 1.62 156.9157.910.863256410.807 1.3 157.9158.910.863256420.522 18.653.43m @ 10.52 g/tTrue Width158.9159.910.863256430.098 3.93159.9160.910.863256440.148 13.1160.9161.910.863256450.046 6.38161.9162.910.863256460.091 1.47 162.9163.910.863256470.169 0.76 163.9164.910.863256480.116 4.72 164.9165.910.863256490.088 1.76 165.9166.910.863256510.656 1.31 166.9167.910.863256520.307 1.37 167.9168.910.863256530.107 1.38 168.9169.910.863256540.247 1.19 169.9170.80.90.773256553.641.63m @ 2.53% True Width2.87 170.8171.810.863256561.542.66 171.8172.40.60.513256570.163 1.04 172.4173.410.863256580.136 0.08 173.4174.20.80.693256590.021 0.01 174.21750.80.693256610.582 0.35 17517610.863256621.57 0.71 17617710.863256630.097 2.01 177177.250.250.213256640.034 0.04 177.251780.750.643256660.507 0.34 17817910.863256670.103 0.24 17918010.863256680.261 0.62 18018110.863256690.1 0.54 181181.50.50.433256710.183 0.24 181.5182.510.863256720.018 0.01 182.5183.510.863256730.006 0.01 Figure 1. Gold mineralized drill core from hole 25-TVA-003 - 156.86m - 162.65m. Interval 157.9m to 161.9m yielded a composite grade of 10.52 g/t Au.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10818/282604_8fb84a54641daa6e_002full.jpgFigure 2. Map of 2025 and Soviet era diamond drillholes in the north-central portion of Military Metals Trojárová Project.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10818/282604_8fb84a54641daa6e_003full.jpgTable 2. Drillhole collar information for the Company's 2025 diamond drilling campaign at Trojárová. Locations presented are final and determined by a professional and qualified surveyor. WGS 84 / UTM Zone 33N DrillholeEastingNorthingElevation (m)Length (m)DipAzimuth25-TVA-0016626965358601640292.2-6522025-TVA-0026626855358668655289.7-7522025-TVA-0036625515358701634200.2-6522525-TVA-0046624755358809604256.5-5522525-TVA-0056623945358812580196-6023025-TVA-006662211535879556962.4-5722025-TVA-007662170535885255986.5-60210 Analytical and QA/QC ProceduresThe program was completed using PQ and HQ sized drill core. Sampled intervals were identified by logging geologists and assigned a unique sample identification number. Samples were split in two halves using a diamond bladed saw with one half remaining in the core box as a permanent record and the half placed in a plastic sample bag, both marked with a waterproof tag bearing the unique sample number which was also written on the sample bag in permanent marker. Samples were transported from the Company's secure facility by private courier to ALS Laboratories in Romania for geochemical analysis. ALS Laboratories is an independent ISO/IEC 17025:2017 and ISO 9001:2015 certified commercial laboratory with no relationship to the Company. The samples were analyzed using multi-element package ME_ICP41a and for gold using fire assay package Au-AA25. ME_ICP41a is an ore grade package involving digestion of a 0.4g sample by aqua regia with an Inductively coupled plasma - atomic emission spectrometry (ICP-AES) finish. The Au-AA25 fire assay method is an ore grade analysis using a 30g aliquot. The aliquot is mixed with flux composed of PbO and SiO2 with variable amounts of borax, soda ash and other reagents. The flux and sample are mixed, then heated at high temperature (>1,000°C) to decompose rock lattices and allow gold within the sample to be collected into a lead button. The button is placed in a porous cupel and heated again in an oxidizing environment to convert lead to lead oxide that is absorbed into the cupel, leaving the precious metals behind as a doré bead or prill. The gold content of the prill is then determined by atomic adsorption spectrometry.Both analyses are preceded by the preparation package Prep-31Y whereby the entire sample is crushed to 70% passing 2mm, a 250g split is collected by rotary splitter and pulverized to 85% passing 75 microns. Laboratory over-limits analysis methods were applied as required for both Sb and Au. A systematic QAQC protocol was employed that includes systematic insertion in the sample stream of certified reference materials and blank samples at a frequency of 1 in 10, plus analysis of duplicate pulp splits at a frequency of 1 in 30.About the Project and Historical ResourceDiscovered in the late 1970s, Trojárová was the focus of extensive surface and underground exploration over a 2km strike length from 1983 to 1995, with 63 core holes for a total of 14,330m, and 1.7km of underground workings completed. Efforts continued over the years as additional trenches were dug, and holes were drilled. Starting in 1990, underground development work began ultimately comprising a 300-meter-long adit connected to a 700-plus meter-long drive in the footwall of the mineralized zone with seven crosscuts into the mineralized zone for sampling purposes.These efforts culminated in a comprehensive study comprising drill logs, analyses, drill plans, maps and sections, deposit model studies, petrographic studies, metallurgical studies and more, now detailed in a multi-volume compendium of reports produced by the Slovak Geological Institute published in 1992, including a historical mineral resource estimate (see "Historical Resource Estimates" below). Per this historical estimate, at a cut-off grade of 1.0% antimony, Trojárová hosts 2.46 million tonnes averaging 2.47% antimony and 0.635 grams per tonne gold in a mineralized zone averaging 3.32 meters wide, containing approximately 60,000 tonnes of antimony in situ.Historical Resource EstimatesThe historical estimate related to the Trojárová Property was taken from a compendium produced by the Slovak Geological Survey, completed in March 1992 based on exploration work undertaking in the 1980s and 1990s. It is entitled (English translation): "FINAL JOB REPORT, PEZINOK-TROJAROVA, Geological Survey State Enterprise", report compendium number 78406 (Michel et al, 1992).The Slovak Geological Institute, the state agency that carried out all exploration and underground development work at Trojárová, classified the historical resources as "P1" and "C2" in the Slovak version of the Russian classification system, respectively. These are closest within the Canadian Institute of Mining, Metallurgy & Petroleum's ("CIM") classification system to "inferred mineral resources," which is defined by the CIM as that part of a mineral resource for which quantity and grade or quality are estimated on the basis of limited geological evidence gathered through appropriate sampling techniques from locations such as outcrops, trenches, pits, workings and drill holes.The historical work carried out appears comprehensive, detailed and at a professional standard. The Company considers this historical data to be relevant as the Company will use these data as a guide to plan future exploration programs. The Company also considers the data to be reliable for these purposes. A qualified person has not done sufficient work to classify the historical estimate as current, and the Company is not treating the historical estimate as current.Qualified PersonThe technical contents of this release were reviewed and approved by David Murray, P.Geo, VP-Exploration for Military Metals and a qualified person as defined by National Instrument 43-101.For more information about Military Metals Corp. and its critical minerals initiatives, please visit: https://www.militarymetalscorp.com.LinkedIn: https://www.linkedin.com/company/military-metals/X: https://x.com/militarymetalsFacebook: https://www.facebook.com/profile.php?id=61564717587797About Military Metals Corp. The Company is a British Columbia-based mineral exploration company that is primarily engaged in the acquisition, exploration and development of mineral properties with a focus on antimony.ON BEHALF OF THE BOARD of DIRECTORSFor more information, please contact:Scott EldridgeCEO and Directorscott@militarymetalscorp.com or info@militarymetalscorp.comFor enquiries, please call 604-537-7556Forward-Looking StatementsThis news release contains "forward-looking information". Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking information in this news release includes the timing of the mineral resource estimate being currently conducted, and its completion at all, future drilling and exploration work at Trojárová, the continuation of the value of antimony, and the future needs of Europe and the E.U. specifically. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this news release. These include geopolitical developments related to the supply and value of antimony, the continued use of antimony and availability of alternatives, availability of capital and labour in respect of the property that is the subject of this news release, the results of any future exploration activities, which cannot be guaranteed, and any other future activities in respect of the property held by the Target. Additional risk factors can also be found in the Company's public filings under the Company's SEDAR+ profile at www.sedarplus.ca. Forward-looking statements contained herein are made as of the date of this news release and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward looking statements if circumstances, management's estimates or opinions should change, except as required by securities legislation. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282604 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

BRUSSELS, BELGIUM, Feb 4, 2026 - (ACN Newswire via SeaPRwire.com) - Airwheel recently announced the continued rollout of its AI-driven rideable smart cabin suitcase solutions, marking a new phase in the evolution of intelligent travel mobility as global demand for smart transportation accelerates. Today, Airwheel’s sales and distribution network spans 68 countries and more than 4,600 retail locations worldwide. As its global expansion continues, the company’s electric and smart suitcases are transitioning from innovative products into high-frequency travel tools used by consumers around the world.Looking ahead, Airwheel will continue to advance the evolution of rideable smart luggage across technology, user experience, and application scenarios, allowing intelligent systems to integrate into travel in a more natural and intuitive way—so that travel becomes not just a means of transportation, but an opportunity to explore the world and enjoy life.As smart mobility continues to reshape global travel and transportation, intellectual property and design capability have emerged as key factors distinguishing true industry leaders from short-term innovators. In the field of rideable suitcase and smart mobility solutions, Airwheel has steadily strengthened its leadership position through long-term, systematic investment in technology and design.As one of the pioneers of the rideable smart luggage category, Airwheel has built a clear and robust competitive moat at the core technology level. To date, the company has accumulated more than 600 patents worldwide, covering critical areas such as motion control algorithms, electric drive systems, intelligent sensing, and structural design, including multiple international invention patents. In parallel, Airwheel has advanced its global intellectual property strategy, with trademarks registered in more than 168 countries and regions, providing a solid foundation for regulatory compliance, large-scale commercialization, and long-term brand development across international markets.Amid the rapid iteration of smart mobility products, design capability has become an equally important measure of product maturity. If patents represent technological depth and engineering strength, then international design awards serve as authoritative recognition of product philosophy, user experience, and comprehensive design excellence. In recent years, multiple Airwheel smart products have received recognition from leading global design awards, including the German iF Design Award, the U.S. IDEA Awards, the IAI Design Award, and the Berlin Design Award, demonstrating the brand’s consistent and high-level design output in the smart mobility space.These awards go far beyond aesthetics, evaluating products across dimensions such as usability logic, safety architecture, engineering integrity, human–machine interaction, and future application potential. Recognition from such professional juries indicates that Airwheel’s smart suitcase designs have been rigorously validated for both functional completeness and real-world usability, further enhancing the brand’s credibility in global markets.At the product level, the global popularity of the Airwheel SE3S Series marks a significant milestone in bringing rideable smart luggage into the mainstream. True product maturity is not defined solely by technical completeness, but by its ability to enter popular culture and everyday consumer awareness. Driven by social media and short-form video platforms, the Airwheel SE3S Series has become a favored electric suitcase among international celebrities, content creators, and fashion-forward travelers—often described as both a mobility tool and a “mobile lifestyle accessory.”Frequently seen in airports, fashion events, street photography, and travel scenarios, this rideable smart cabin suitcase not only serves a functional purpose but also delivers emotional value and personal expression. According to public data and platform analytics, content related to the Airwheel SE3S Series has generated tens of billions of impressions globally, transcending the boundaries of a single product category and becoming widely recognized as a fashionable travel symbol in the digital era.User feedback has further reinforced this dual identity. Many consumers describe the SE3S Series as “instantly recognizable” and “a travel companion that makes journeys lighter and more enjoyable,” strengthening its positioning at the intersection of smart mobility and lifestyle consumption.Notably, Airwheel has expanded its smart luggage ecosystem beyond adult users. The company also offers the SQ3 Series, a rideable smart suitcase designed specifically for children. By prioritizing safety and structural stability, the SQ3 Series introduces greater interaction and enjoyment into family travel, positioning smart luggage as an integral part of the parent-child travel experience.From a compliance perspective, the Airwheel SE3S Series is designed as a cabin suitcase, featuring a detachable lithium battery that meets airline safety standards, allowing it to be carried onboard flights in accordance with major international airline regulations. This design enables frequent, legal, and reliable use in airport environments worldwide, making it a practical choice for international travelers.Evolving from a mobility device into a source of emotional value and, ultimately, a widely recognized fashion travel product, the rise of the Airwheel SE3S Series signals that rideable smart luggage is becoming a natural part of everyday global travel.About AirwheelFounded in 2004, Airwheel is a global smart transportation device manufacturer with R&D, marketing, manufacturing, and logistics centers in the United States, Belgium, and China. The company has integrated the portable transportation industrial chain and built a globally recognized brand, serving more than 30 million users across 68 countries. Guided by its philosophy of “Free Intelligent Life,” Airwheel leverages technologies such as IoT sensors, robotics, and deep learning to develop intelligent mobility solutions that enhance freedom, joy, and everyday travel experiences worldwide.Media ContactCompany: AirwheelContact: Media TeamWebsite: https://www.airwheel.net Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - February 3, 2026) - Casa Minerals Inc. (TSXV: CASA) (OTCQB: CASXF) (FSE: 0CM) (the "Company" or "Casa"), is pleased to announce the closing of the first tranche of its previously announced non-brokered private placement (the "Offering"). The Company has closed on a total of 4,917,000 units (each, a "Unit") at a price of $0.125 per unit for gross proceeds of up to $614,625.00.Each Unit consists of one common share of the Company (a "Share") and one common share purchase warrant (each full warrant, a "Warrant"). Each of the 4,917,000 Warrants entitles the holder to acquire one additional share for a period of two years until February 04, 2028. The warrant exercise strike price is $0.15/share in the first three months and automatically converts to $0.20 per share then after for the remainder of the two years period.All issued Securities will be subject to a 4-month and one day hold-period, during which any resale or other transfer will be restricted in accordance with applicable securities laws.A Finder's Fees of $24,000 has been paid to registered financial institutions.Net proceeds from the offering will be used for general administration, exploration and development activities on the Company's projects in Arizona, and British Columbia, Canada. The Company will continue to raise the remaining placement in the coming week.The completion of the private placement remains subject to approval of the TSX Venture Exchange.None of the securities issued in the Offering will be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act.About Casa Minerals Inc.The Company is engaged in the acquisition, exploration and development of mineral properties located in Canada and the USA. Casa owns ninety percent (90%) interest in the Congress gold mine (Arizona, USA). Additionally, the Company owns a one hundred percent (100%) interest in the polymetallic Pitman (BC, Canada) and has an option to acquire a seventy-five percent (75%) interest in the Arsenault VMS Property (BC, Canada).On Behalf of Board of Directors,Farshad Shirvani, M.Sc. GeologyPresident and CEOFor more information, please contact:Casa Minerals Inc.Farshad Shirvani, President & CEOPhone: (604) 678-9587Email: contact@casaminerals.comhttps://www.casaminerals.comNEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282620 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ROMEOVILLE, IL, Feb 2, 2026 - (ACN Newswire via SeaPRwire.com) - Formerra, a leader in performance materials distribution, today announced an expanded distribution agreement that brings Evonik's CARE brand healthcare grades into Formerra's medical portfolio. Covering the United States and Canada, the agreement creates new access points for high-performance polyamides used in essential healthcare applications.This expansion kicks off at MD&M West 2026 this week, and underscores both companies' commitment to supporting the healthcare market with high-performance materials, responsive service, and continuity of supply. It also builds on the companies' two-year partnership, which introduced Evonik's VESTAMID® and TROGAMID® families to Formerra's engineered materials lineup.With this expansion, Formerra will support Evonik healthcare grades designed for fluid handling, drug delivery, diagnostic systems, surgical instrument parts, medical device housings, components that see short-term body contact (< 30 days), and other non-implantable applications requiring strength, clarity, chemical resistance, and consistent processing.Key medical grade materials include:VESTAMID® Care ML PA12VESTAMID® Care ME PEBA elastomerTROGAMID® Care MX microcrystalline PA"Our healthcare customers rely on stable supply, world-class regulatory support, and materials that perform under demanding conditions," said Steve Harmon, Director, Key Accounts, Formerra. "Evonik's healthcare grades bring the combination of durability, processing consistency, and documentation support that medical manufacturers require. This expansion lets us strengthen the technical resources and materials pipeline available to teams developing next-generation devices.""Formerra's ability to serve the whole supply chain in the medical space, from design companies to compounders to medical device OEMs, with technical rigor and exceptional logistics and with already-proven successful demonstration in the industrial space, made this expansion with CARE brand Polyamide 12 products a natural step," said Basker Lalgudi, Business Manager, Global Medical Devices, Evonik. "Their healthcare expertise and focus help customers select and implement our materials with confidence across a range of critical applications."By adding Evonik's healthcare CARE brand materials, Formerra will offer customers a proven set of polyamide solutions that support regulatory pathways, design requirements, and long-term reliability. Formerra's team will provide material selection guidance, processing support, and regional supply chain readiness to help OEMs and molders accelerate development cycles.Formerra will exhibit at MD&M West in Booth 2266 in Anaheim, California, Feb. 3-5, 2026.Key Details:Formerra will distribute Evonik's CARE brand healthcare grades across the U.S. and Canada.Materials include healthcare grades within the VESTAMID® L, VESTAMID® E, and TROGAMID® CX families, plus designated sustainable options.The agreement strengthens Formerra's medical portfolio and expands its support for fluid management, diagnostics, wearables, and device housings.Formerra will provide application guidance, regulatory documentation support, and supply chain continuity for medical customers.About FormerraFormerra is a preeminent distributor of engineered materials, connecting the world's leading polymer producers with thousands of OEMs and brand owners across healthcare, consumer, industrial, and mobility markets. Powered by technical and commercial expertise, it brings a distinctive combination of portfolio depth, supply chain strength, industry knowledge, service, leading e-commerce capabilities, and ingenuity. The experienced Formerra team helps customers across multiple industries to design, select, process, and develop products in new and better ways, driving improved performance, productivity, reliability, and sustainability. To learn more, visit www.formerra.com.About EvonikEvonik goes beyond the boundaries of chemistry with its combination of innovative strength and leading technological expertise. The global chemical company, headquartered in Essen, Germany, is active in more than 100 countries and generated sales of €15.2 billion and earnings (adjusted EBITDA) of €2.1 billion in 2024. The common motivation of the approximately 32,000 employees: to provide customers with a decisive competitive advantage with tailor-made products and solutions as a superforce for industry, thereby improving people's lives. In all markets. Every day. To learn more, visit www.evonik.com.Media ContactJackie MorrisMarketing Communications Manager, Formerrajackie.morris@formerra.com+1 630-972-3144SOURCE: Formerra Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

MIAMI, FL, Feb 2, 2026 - (ACN Newswire via SeaPRwire.com) - Digi Power X Inc. ("Digipower X" or the "Company") (Nasdaq:DGXX)(TSXV:DGX), a vertically integrated AI infrastructure company focused on the deployment of Tier-3 modular data centers powered by owned and controlled energy assets, today announced that Hans Vestberg, former Chairman and Chief Executive Officer of Verizon Communications, has joined the Company as a senior advisor serving on its Advisory Board to support the Company's expansion strategy.Mr. Vestberg brings more than three decades of global leadership in mission-critical infrastructure, telecommunications networks, and large-scale capital deployment. He is widely recognized for leading Verizon's first commercial 5G deployment in 2018 and for advancing nationwide fiber, mobile edge computing, and next-generation network architectures.Prior to Verizon, Mr. Vestberg spent nearly three decades at Ericsson, including almost seven years as its Chief Executive Officer, where he helped build and operate global infrastructure facilitating approximately 35% of worldwide mobile traffic.Mr. Vestberg's appointment comes at a time when AI adoption is increasingly constrained, not by software or silicon, but by power availability, cooling capacity, and deployment speed. Digipower X is working on addressing this challenge through the deployment of the AI-Ready Modular Solution (ARMS) platform, designed to deliver Tier-3 modular AI data centers within approximately 180 days, supported by a vertically integrated power strategy and a growing portfolio of large-scale energy assets."Hans Vestberg built and scaled the physical infrastructure that helped enable the fiber, mobile, and 5G revolutions," said Michel Amar, Chairman and Chief Executive Officer of Digipower X. "He understands what most of the market overlooks: AI's bottleneck isn't algorithms or chips, it's power, cooling, and deployment speed. Hans knows how to execute infrastructure transformation at a national and global scale, and we expect his guidance will be invaluable as we expand our modular AI data center footprint.""I've spent over 30 years building the networks that move data," said Mr. Vestberg. "The next decade is about building the infrastructure that processes it. Digipower X is more than just a data center company. It controls its power, is developing the ability to deploy Tier-3 infrastructure in the near term, and is building a modular platform to address the exact constraints holding back large-scale AI deployment. Its focus on power availability and deployment speed first, real estate second, is exactly the right approach."Infrastructure Experience Aligned with AI ScaleDuring his tenure at Ericsson (2010-2016), Mr. Vestberg led more than 115,000 employees worldwide and positioned the company at the forefront of next-generation wireless technologies. At Verizon (2018-2025), he reshaped the organization around a network-first strategy, oversaw major investments in spectrum and fiber, and advanced distributed edge-compute capabilities to enable data-intensive and latency-sensitive applications.Mr. Vestberg insightfully noted at Davos 2024 that "one of the most important infrastructures of this century is digital infrastructure," and that AI workloads will increasingly migrate from centralized hyperscale facilities toward distributed locations supporting real-time inference and enterprise demand.Mr. Vestberg currently serves as a board member of BlackRock and Verizon.Addressing the Power and Deployment Constraint in AI InfrastructureDigipower X operates a combined-cycle power plant and three additional operating sites, with more than 200 megawatts of power currently online. The Company has secured development capacity to support AI infrastructure expansion over the next three years, with the ability to develop up to an additional 1.5 gigawatts of power capacity, including at major sites in North Carolina and West Virginia.In West Virginia, Digipower X has entered into a letter of intent relating to a 1.3-gigawatt power plant, which is being evaluated as a long-term site for AI data center and advanced computing infrastructure deployment."Hans recognizes that national AI competitiveness depends on solving power availability and deployment speed," said Gerard Rotonda, Board Member of Digipower X and former CFO of Deutsche Bank Wealth & Asset Management Americas. "His experience aligns directly with Digipower X's mission to deliver infrastructure at the scale and speed this market now requires."Vestberg's Strategic FocusIn his advisory role, Mr. Vestberg will work closely with Digipower X's executive team on:AI infrastructure deployment strategy and scaling frameworks;Distributed and edge-compute architectures for inference-driven workloads;Strategic partnerships with hyperscalers, enterprises, and infrastructure stakeholders;Power optimization and energy-efficient data center design;Tier-3 redundancy and mission-critical reliability standards; andInternational expansion strategy and site prioritization.About Digipower XDigipower X is an innovative energy infrastructure company that develops Tier III-certified modular AI data centers and drives the expansion of sustainable energy assets.For further information, please contact:Michel Amar, Chief Executive OfficerDigipower X Inc.www.digipowerx.comInvestor RelationsT: 888-474-9222Email: IR@digihostpower.comCautionary StatementTrading in the securities of the Company should be considered highly speculative. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Forward-Looking StatementsExcept for the statements of historical fact, this news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") that are based on expectations, estimates and projections as at the date of this news release and are covered by safe harbors under Canadian and United States securities laws. Forward-looking information in this news release includes information about the Company's expectations concerning the potential contributions by our new advisor to the Company's strategic efforts, the potential further improvements to profitability and efficiency across the Company's operations, including, as a result of the Company's expansion efforts, potential for the Company's long-term growth and clean energy strategy, and the business goals and objectives of the Company. Factors that could cause actual results to differ materially from those described in such forward-looking information include, but are not limited to: delivery of equipment and implementation of systems may not occur on the timelines anticipated by the Company or at all; future capital needs and uncertainty of additional financing; share dilution resulting from equity issuances; risks relating to the strategy of maintaining and increasing Bitcoin holdings and the impact of depreciating Bitcoin prices on working capital; statements regarding the timing, scale and expansion of AI and high-performance computing infrastructure; changes in demand for AI and high-performance computing; future data center capacity may not be realized at the level anticipated by the Company, or at all; development of additional facilities and installation of infrastructure to expand operations may not be completed on the timelines anticipated by the Company, or at all; ability to access additional power from the local power grid; the Company may not be able to profitably liquidate its current digital currency inventory, or at all; a decline in digital currency prices may have a significant negative impact on the Company's operations; the volatility of digital currency prices; and other related risks as more fully set out in the Annual Information Form of the Company and other documents disclosed under the Company's filings at www.sedarplus.ca and www.SEC.gov/EDGAR. The forward-looking information in this news release reflects the current expectations, assumptions and/or beliefs of the Company based on information currently available to the Company. In connection with the forward-looking information contained in this news release, the Company has made assumptions about, among other things, profitable use of the Company's assets going forward; the demand for data center capacity for AI and high-performance computing; and there will be no regulation or law that will prevent the Company from operating its business. The Company has also assumed that no significant events occur outside of the Company's normal course of business. Although the Company believes that the assumptions inherent in the forward-looking information are reasonable, forward-looking information is not a guarantee of future performance and accordingly undue reliance should not be put on such information due to the inherent uncertainties therein. The Company undertakes no obligation to revise or update any forward-looking information other than as required by applicable law.SOURCE: Digi Power X Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

NEEDHAM, MA, Feb 2, 2026 - (ACN Newswire via SeaPRwire.com) - Bioxytran, Inc. (OTCQB: BIXT) (“Bioxytran” or the “Company”), a clinical-stage biotechnology company developing platform technologies spanning glycovirology, hypoxia, and degenerative diseases, announced the execution of a Sponsored Research Agreement with the University of Minnesota to support advanced biochemical research aimed at improving the understanding and development of novel polysaccharide and oligosaccharide interactions with biologically relevant targets.Under the agreement, research will be conducted at the University of Minnesota under the direction of Dr. Kevin Mayo, a recognized expert in biomolecular structure and nuclear magnetic resonance spectroscopy The collaboration is designed to further characterize carbohydrate-binding interactions that may play a role in future therapeutic and diagnostic applications.“This collaboration with the University of Minnesota represents an important step in strengthening the scientific foundation behind our carbohydrate-based technology platform,” said David Platt, CEO of Bioxytran. “By leveraging the University’s deep expertise in structural biology and advanced nuclear magnetic resonance spectroscopy, we aim to generate high-quality data that supports the continued evolution of our research and development pipeline.”Research FocusThe sponsored research program will explore how specific polysaccharides and related carbohydrate structures interact with target molecules relevant to biological systems. Using state-of-the-art nuclear magnetic resonance methodologies, the research team will analyze binding interactions, structural conformations, and affinity characteristics of select carbohydrate compounds. The work is expected to build on Bioxytran’s existing research into carbohydrate-based materials and their potential applications across biomedical and life-science domains. Findings from the study may help guide future development strategies and inform additional preclinical research initiatives.Academic–Industry CollaborationThe agreement reflects a shared commitment to advancing scientific knowledge through collaboration between academia and industry. The University of Minnesota will carry out the research in accordance with its established academic standards, ensuring scientific rigor, transparency, and adherence to institutional research policies.This type of partnership exemplifies how academic research institutions and innovative companies can work together to address complex scientific questions,” said Dr. Kevin Mayo, Principal Investigator and Professor at the University of Minnesota. “Our goal is to apply advanced analytical tools to generate insights that are both scientifically meaningful and relevant to real-world applications.”Timeline and StructureThe research term is expected to run through early 2027, with defined milestones, periodic progress reviews, and structured reporting. Bioxytran will provide funding to support research personnel, nuclear magnetic resonance facility access, and associated laboratory resources required to execute the program. In accordance with standard sponsored research practices, the University of Minnesota will retain ownership of any intellectual property generated through the research, while Bioxytran will receive broad rights to use the resulting research data for internal research and development purposes.Strategic SignificanceFor Bioxytran, the collaboration supports a broader strategy focused on strengthening its scientific validation, expanding academic partnerships, and advancing next-generation carbohydrate technologies. The company believes that well-characterized molecular interactions are a critical step toward unlocking new therapeutic pathways and accelerating innovation.The University of Minnesota continues to be recognized globally for its leadership in biomedical research and technology transfer, making it an ideal partner for companies seeking to bridge fundamental science and commercial development.About the University of MinnesotaThe University of Minnesota is one of the nation’s leading public research universities, known for its commitment to discovery, innovation, and the translation of research into real-world impact. Through industry partnerships and sponsored research programs, the University fosters collaboration that advances science and benefits society.About Bioxytran, Inc.Bioxytran is a clinical-stage pharmaceutical company developing platform technologies in glycovirology, hypoxia and degenerative diseases using carbohydrate drug design, including programs that leverage galectin inhibition and programs that aim to address hypoxic conditions and tissue oxygenation. Bioxytran’s common stock trades on the OTCQB under the symbol BIXT.Company Contact:Bioxytran, Inc.75 Second Avenue, Needham, MA 02494Phone: 617‑454‑1199Email: info@Bioxytraninc.comWeb: www.Bioxytraninc.comForward-Looking StatementsThis press release contains forward-looking statements, including statements regarding anticipated regulatory interactions, future clinical trials, trial designs, timing of data submission and publication, and potential therapeutic and commercial opportunities. Forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Readers are urged to review the Company’s risk factors disclosed in its reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10‑K for the year ended December 31, 2024. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TSUKUBA, Japan, Feb 2, 2026 - (ACN Newswire via SeaPRwire.com) - Modern industry relies heavily on catalysts, which are substances that speed up chemical reactions. They’re vital in everything from manufacturing household chemicals to generating clean energy or recycling waste. However, designing new catalysts is challenging because their performance is affected by many interacting factors.A new tool uses a catalyst gene profiling, where catalysts are represented as symbolic sequences, making it easier for scientists to interpret data and design catalysts without a need for programming skills.A new tool developed by researchers at Hokkaido University, published in Science and Technology of Advanced Materials: Methods, will simplify the process by providing researchers with a way to easily view and explore data about catalysts, enabling them to identify patterns and relationships in catalyst datasets without needing advanced programming or computational skills.The tool takes advantage of an approach known as catalyst gene profiling, where catalysts are represented as symbolic sequences. This makes it easier for scientists to interpret the data and apply sequence-based analysis methods to design and improve catalysts. The tool itself is a web-based graphical interface that offers an intuitive and interactive way to investigate these catalyst profiles.“The system enables researchers to explore complex catalyst datasets, identify global trends, and recognize local features—all without requiring advanced programming skills,” explains Professor Keisuke Takahashi, who led the study. “By visualizing both the relationships among catalysts and the underlying gene-based features, the platform makes catalyst design more interpretable, accessible, and efficient, bridging the gap between data-driven analysis and practical experimental insight.”Users can view catalysts clustered together based on how similar their features are or how similar their sequences are. The tool also includes a heat map that offers insights into how the catalyst gene sequences are calculated. The different visualizations can be viewed side by side and are synchronized so they all update simultaneously when a user zooms in or selects a group of catalysts.The team plans to extend the tool to work with other material science datasets so it can be used more broadly in the field. They’re also working to include a predictive component. Integrating modeling and editing strategies would mean researchers could use the tool not only to explore existing catalysts but also to investigate new ideas for high-performance materials. In addition, they want to improve the tool’s collaborative features so that several researchers can work together to explore and annotate datasets, enabling a community-oriented, data-driven approach to material design and discovery.“Our goal is to make advanced materials research more intuitive, approachable, and impactful,” says Takahashi.Further informationKeisuke TakahashiHokkaido University keisuke.takahashi@sci.hokudai.ac.jpPaper: https://doi.org/10.1080/27660400.2025.2600689 About Science and Technology of Advanced Materials: Methods (STAM-M)STAM Methods is an open access sister journal of Science and Technology of Advanced Materials (STAM), and focuses on emergent methods and tools for improving and/or accelerating materials developments, such as methodology, apparatus, instrumentation, modeling, high-through put data collection, materials/process informatics, databases, and programming. https://www.tandfonline.com/STAM-MDr Kazuya SaitoSTAM Methods Publishing Director SAITO.Kazuya@nims.go.jpPress release distributed by Asia Research News for Science and Technology of Advanced Materials. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

NEW YORK, Feb 1, 2026 - (ACN Newswire via SeaPRwire.com) - TCG.Zone (The Collectors Grid), a key player in the global collectibles infrastructure and ecosystem, has officially unveiled its strategic shift toward prioritizing investments in high-value, rare collectible assets. This strategic realignment underscores the company’s commitment to tapping into the long-term value and cultural significance of elite collectibles, with the recent participation in a high-profile international auction serving as a pivotal first step in this new direction.Recently, the world's only Pokémon card graded PSA 10 - Pikachu Illustrator - once again became a focal point of global attention across the collectibles and cultural landscape. As a long-term contributor to TCG infrastructure and the broader collectibles ecosystem, The Collectors Grid(TCG.Zone) participated in and witnessed this historically significant moment.Recognized as one of the most iconic works in Pokémon card history, Pikachu Illustrator is distinguished not only by its extreme rarity, but also by its symbolic representation of Pokémon culture, artistic value, and generational memory.The Legendary Status of the World's Only PSA 10According to publicly available information, the world's only PSA 10 "Pikachu Illustrator" card is currently owned by Logan Paul. The card was involved in a high-profile transaction in 2022, valued at nearly USD 5.3 million, marking a defining milestone in the history of Pokémon card collecting.The Industry Significance of Goldin AuctionsAlthough Logan Paul's acquisition of the card did not take place through Goldin, the Goldin auction platform has continued to play an important role in the card's contemporary circulation and visibility. As one of the world's most influential high-end collectibles auction platforms, Goldin's auction framework and the attention it generates brought renewed global focus to this legendary card, further positioning Pokémon cards within the broader mainstream collectibles market.Netflix Documentary Captures a Cultural MomentAmid the phenomenon-level attention generated by this card on the Goldin platform, Netflix documented the full auction process and produced a dedicated documentary. Approached from a cultural and historical perspective, the documentary highlights the unique position of Pikachu Illustrator within the modern collectibles ecosystem, elevating it beyond price alone and framing it as a lasting cultural reference.Global Participation and TCG.Zone's InvolvementThe discussions and auction activity surrounding Pikachu Illustrator attracted participation from top collectors, institutions, and professional teams from around the world. TCG.Zone was among the active participants in the bidding process. During the auction, TCG.Zone submitted a bid of USD 5,000,000. Although the bid was ultimately surpassed by a higher offer, TCG.Zone remained deeply engaged throughout the process and witnessed this pivotal moment firsthand.Continuing to Follow the Card's Future TrajectoryIn post-auction interviews, TCG.Zone stated that this participation does not mark an endpoint. The team will continue to closely monitor the movement and future trajectory of the world's only PSA 10 Pikachu Illustrator, and does not rule out participating again should the right opportunity arise. This event represents more than an auction. It stands as a collective reflection on rarity, cultural identity, and long-term value.The story of Pikachu Illustrator continues to unfold,and remains an enduring chapter in the global history of Pokémon card collecting.About TCGThe Collectors Grid is an on-chain infrastructure designed to formalize collectibles as a structured asset class. By integrating provenance, ownership, pricing, and settlement at the protocol level, it addresses long-standing inefficiencies in the global collectibles market. The platform enables institutional-grade transparency while preserving the unique characteristics of collectible assets. Positioned as a settlement layer rather than a marketplace, The Collectors Grid provides the foundational rails for liquidity, valuation, and long-term capital participation in cards, IP, and high-value collectibles.Social LinksTwitter: https://x.com/tcgzoneofficialInstagram: https://www.instagram.com/tcgzoneofficial/Telegram: https://t.me/tcgzoneofficialMedia ContactBrand : The Collectors Grid (tcg.zone)Contact: AnnieWebsite: https://www.tcg.zone Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

MOSCOW, Jan 31, 2026 - (ACN Newswire via SeaPRwire.com) - Expert Dialogues were held for the first time within the Open Dialogue framework at the Russia National Centre in Moscow on 30 January. The forum focused on five major megatrends shaping global economic, technological, and social development, bringing together international experts to explore how these forces will influence societies and industries in the decades ahead.Organized by the Russia National Centre in partnership with the Centre for Cross-Industry Expertise "The Third Rome" and supported by the Presidential Executive Office, the forum brought together experts from around the world to discuss economic, technological, and social transformations.Maksim Oreshkin, Deputy Head of the Russian Executive Administration for Global Trends, presented five key megatrends that, he said, are already shaping global development and will continue to influence the world in the coming decades."By 2026, Open Dialogue has become an international platform uniting experts from across the world to discuss the future of the planet, the global economy, and society," Oreshkin said. "Understanding these processes is essential for preparing for change and leveraging it in the interests of nations and, above all, people. Today, I will focus on five key megatrends — while not treating artificial intelligence as a separate trend, because it has already become an integral part of our lives."1. A New Global Economic Paradigm: Globalisation 2.0A shift from traditional globalisation to a more decentralised system was described. BRICS+ countries now play a growing role in the global economy, technological development, and demographic trends, while the Global South is increasingly engaging in direct trade and national-currency settlements."Globalisation hasn't ended; it has changed," Oreshkin said. "Sovereignty — at state, social, and economic levels — is now the key to competitiveness. Only countries that preserve all three levels can lead in a multipolar world."China, the USA, India, and Russia are identified as major global powers, while highlighting emerging growth centres such as Indonesia and "connector countries" like the United Arab Emirates. Digital platforms and decentralised networks are also becoming independent participants in the world economy.2. Platformisation and Institutional AutomationThe second megatrend highlights the rise of platforms and automation across all sectors. Platforms and algorithms are increasingly shaping decision-making in healthcare, education, finance, trade, and beyond."Platform solutions enhance efficiency and reduce transaction costs through self-adjusting algorithms," Oreshkin said. "Countries without technological sovereignty risk becoming dependent on external platforms, which can have strategic consequences during conflicts."3. Transformation of the Global Financial SystemIt was noted that traditional financial models face mounting challenges, including rising public debt, widening inequality, and geopolitical fragmentation. Technologies such as blockchain, artificial intelligence, and digital platforms are creating alternative financial mechanisms, including decentralised finance."The traditional model of cross-border payments is under pressure. Decentralised systems and digital technologies are reshaping the financial system," he said.4. Demographic Shifts and ChallengesThe fourth megatrend concerns global population dynamics. Global fertility rates have fallen sharply, with some countries facing critical declines. By the end of the 21st century, the working-age population may shrink significantly, while the proportion of elderly people rises, placing pressure on pension systems and social services."Even in Africa, the ratio of elderly to working-age population will rise to 30%, and globally to 56%," Oreshkin explained. "Education demand will decrease, but healthcare and social service needs will grow. These interconnected trends will amplify each other."5. Human Capital Development in the Technological EraThe final megatrend focuses on human capital in a rapidly changing technological environment.Autonomous systems, digital platforms, and artificial intelligence are transforming education, work, and healthcare, while biotechnologies expand human capabilities."AI is both a challenge and an opportunity," Oreshkin said. "It allows personalized learning paths and supports teachers.Professions are changing: mid-level specialists will be in demand, and companies must retrain employees from junior positions. The social sphere will also evolve, ensuring active longevity in the new demographic era."Global PerspectiveThroughout the presentation, Oreshkin illustrated each trend with real-life examples from different continents: a manager from Asia, a farmer from Africa, and a homemaker from Eastern Europe. He highlighted that innovations in Africa could improve education and healthcare, Eastern Europe may see rising living standards and more efficient social systems, and Asia will require reskilling to meet changing labor demands."The world has entered a period of significant change in finance, demography, and other spheres. States, companies, and individuals must be prepared. Those who understand and adapt will shape the future," Oreshkin concluded.Open Dialogue on AirThis year, Open Dialogue introduced a podcast format — Open Dialogue on Air — featuring global experts discussing key trends in international development. Participants include award-winning Chinese sci-fi writer Chen Qiufan, Dr. Selina Neri of the Future Readiness Academy, Dr. Rais Hussin of EMIR Research (Malaysia), Prof. Wang Feng of UC Irvine, and global strategist Dr. Parag Khanna.First held in April 2025 at the Russia National Centre, the Open Dialogue brought together over 3,000 experts from dozens of countries. By presidential decree, it will now be held annually.Social LinksTelegram: https://t.me/gowithrussiaVK: https://vk.com/gowithrussiaOK: https://ok.ru/gowithrussiaDZen: https://dzen.ru/gowithrussiaContact for the mediaBrand: Russia National CentreContact: Media teamEmail: Pressa@russia.ru Website: https://russia.ruEssay Submission: https://dialog.russia.ru/en/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, Jan 30, 2026 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received approval from the National Medical Products Administration of China (NMPA) on 30 January 2026 for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. It is the first and only targeted drug approved in China for vitiligo, addressing a significant unmet clinical need.Ruxolitinib phosphate cream is the first and only drug approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for repigmentation in nonsegmental vitiligo[1,2]. Prior to receiving formal NDA approval, the Group benefited from the “Early and Pilot Implementation” policy granted to the Hainan Free Trade Port and Lecheng Pilot Zone (“Lecheng Pilot Zone”), the “Hong Kong and Macau Medicine and Equipment Connect” policy, and the clinically urgently needed imported drug policies of the Beijing and Tianjin Free Trade Zones, and had already initiated the pilot application of ruxolitinib phosphate cream. Currently, Boao Super Hospital has prescribed ruxolitinib phosphate cream to over 7,000 patients with non-segmental vitiligo, and more than twenty hospitals in Guangzhou, Shenzhen, Dongguan, Foshan, Zhongshan, Zhuhai, Jiangmen, Huizhou, Beijing and Tianjin have provided prescription services for the Product, demonstrating its clinical potential.The product has shown positive results in both overseas clinical studies and the real-world study in China: in two identical Phase III double-blind, randomized, placebo-controlled studies (TRuE-V1 and TRuE-V2) conducted overseas, the proportion of patients achieving the primary efficacy endpoint of at least 75% improvement in the Facial Vitiligo Area Score Index (F-VASI 75) after 24 weeks of treatment with ruxolitinib phosphate cream was 29.9% in both studies, significantly higher than the 7.5% and 12.9% in the placebo groups, respectively. Continued use up to 52 weeks showed sustained repigmentation[3]. In accordance with the relevant regulations of the Lecheng Pilot Zone's real-world data application pilot project, ruxolitinib phosphate cream underwent real-world study in China, demonstrating positive efficacy consistent with the results of overseas pivotal clinical studies. All secondary efficacy endpoints in both domestic and overseas clinical studies showed a benefit trend consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with prolonged treatment. Furthermore, according to safety monitoring data from the Lecheng Pilot Zone, no new safety event was identified, no adverse event (AE) leading to discontinuation or withdrawal of treatment occurred, and no study drug-related serious adverse event (SAE) occurred.This approval in vitiligo brings new hope for treatment to over 10 million vitiligo patients in China, addressing urgent clinical needs. At the same time, it will add to Dermavon’s product portfolio in the field of skin treatment, potentially synergizing with Dermavon’s commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon's position in the field of skin health.Furthermore, the Phase III clinical trial in China of ruxolitinib phosphate cream for the treatment of mild to moderate atopic dermatitis (AD) has achieved positive results. Currently, the Group is actively advancing the NDA for ruxolitinib phosphate cream for the treatment of AD in China, which, if approved, will provide a new treatment option for a broader patient population with AD in China.About VitiligoVitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[4]. Existing therapies, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical limitations, with adverse reactions or limited efficacy with long-term use. The NDA approval of ruxolitinib phosphate cream successfully fills the gap in targeted drug treatment for vitiligo and is of great landmark significance.More About Ruxolitinib Phosphate CreamRuxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is approved for the topical treatment of nonsegmental vitiligo in adult and patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate AD in patients aged 2 years and older without immunodeficiency in the U.S. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.The Group, through a subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside Mainland China to the Group (excluding Dermavon and its subsidiary).Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference:1. The U.S. FDA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream2. The EMA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar3. The clinical studies information can be found on the Opzelura® official website, as follows:https://www.opzelura.com/opzelura-prescribing-information4. China Insights Consultancy’s industrial reportCMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, January 30, 2026 - (ACN Newswire via SeaPRwire.com) – As China’s first batch of Level 3 (L3) conditionally autonomous driving vehicles receives official market access, advanced smart driving is poised for its inaugural year of commercial explosion. At this pivotal juncture, Cheche Group Inc. (CCG) ("Cheche" or the "Company"), a leading global InsurTech platform, announced the signing of a strategic cooperation agreement with Volkswagen (Anhui) Digital Sales and Services Co., Ltd. (hereinafter "DSSO") and Beijing Cardif Airstar Property & Casualty Insurance Co., Ltd. (hereinafter "Cardif Airstar Insurance").This tripartite collaboration is more than just a deep dive into high-quality growth for New Energy Vehicle (NEV) insurance; it represents a core transition from "digitization" to "intelligence." The partnership establishes three strategic directions for synergy. First, it focuses on the transformation of product formats by leveraging Cheche’s SaaS platform to co-create an integrated "Insurance + Value-Added Services" package, enabling the efficient, one-stop fulfillment of high-value services. Second, it upgrades pricing capabilities by deeply integrating compliant driving data with dynamic vehicle information, utilizing AI-driven risk profiling to achieve differentiated precision pricing while addressing the complex challenge of liability determination in human-machine co-driving scenarios. Finally, it expands the ecosystem dimension by embedding insurance services throughout the vehicle sales and after-sales process, extending the business from a single policy to a full-lifecycle service ecosystem that encompasses renewal management and mobility protection.01. Smart Driving Insurance: Securing "Pricing Authority" in the L3 Mass Production EraTraditional auto insurance has long struggled with "human-machine co-driving" scenarios due to a lack of real-time dynamic data for liability determination and precise risk identification. Having served leading automakers such as Tesla, Li Auto, and Xiaomi, Cheche provides VW Anhui Digital with an embedded SaaS system centered on data attribution and dynamic pricing.Through this SaaS infrastructure, vehicle driving data is seamlessly synchronized with BNP Paribas Star’s actuarial models. This AI-driven joint risk profiling not only resolves the technical difficulties of liability judgment in smart driving scenarios but also delivers a "low-premium rewards for safe drivers," serving as a vital solution to the profitability challenges currently facing the NEV insurance industry.02. Ecosystem Breakthrough: Leveraging the "Xiaomi + Volkswagen DSSO" New Quality Productive ForcesInvestors are closely watching the cross-sector dynamics underpinning this collaboration. Cardif Airstar Insurance was co-founded by Xiaomi Group, Volkswagen Financial Services, and Cardif Airstar Insurance, combining the strengths of an internet giant, a global financial powerhouse, and a leading smart automaker.As the hub connecting these forces with Volkswagen’s Hefei Intelligent Electric Vehicle Center, Cheche is penetrating the world’s top smart driving supply chains. This is not merely system integration; it marks Cheche’s evolution into a digital operator within the "Vehicle-Battery-Charging-Insurance" integrated landscape. Amid policy tailwinds such as "New Quality Productive Forces," Cheche’s closed-loop ecosystem is becoming a definitive growth pole for insurance and tech capital.03. Scenario Transformation: From Transactional Policies to Full-Lifecycle OperationsIn 2026, as the automotive market shifts from a competition over hardware parameters to a competition over user experience, Cheche is helping DSSO deeply couple insurance services with the car-buying and after-sales journey. The integrated service package transforms insurance from a low-frequency tool into a high-frequency touchpoint for user engagement.Christian Koenig, After-sales Director of DSSO, noted that Cheche’s technical foundation allowed the partnership to advance rapidly from a high starting point. This "plug-and-play" empowerment capability, proven by mainstream automakers, has become a technical moat for Cheche in the capital markets.04. Conclusion: The Final Piece of the Trillion-Dollar Blue OceanThe year 2026 marks the point where NEV insurance evolves from scale expansion to intelligent upgrades. Cheche will continue to advance its AI pricing engine, driving the leap from digital to intelligent services.According to data released by the Ministry of Public Security on January 26, China’s NEV ownership reached 43.97 million units by the end of 2025, accounting for 12.01% of the total vehicle population—a growth rate exceeding 40% year-over-year. In this environment, those who define the insurance standards for the smart driving era will control the entry point to future mobility. With its high barriers to entry via OEM partnerships and forward-looking AI layouts, Cheche is racing toward becoming a leader in the trillion-dollar NEV insurance market. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, January 30, 2026 - (ACN Newswire via SeaPRwire.com) – 27 January 2026, Nissin Foods (Hong Kong) Charity Fund (“Charity Fund”) announced its continued support for elite athletes from The Education University of Hong Kong (“EdUHK”) for the fourth consecutive year. The Presentation Ceremony for the Nissin Foods Scholarship for Elite Athletes 2025/2026 was held to honour seven outstanding athletes who not only demonstrate excellence in their respective sports but also aspire to become future educators. The scholarship will cover their full tuition fees throughout their entire study period, enabling them to pursue their academic and athletic goals without financial concerns.Established in 2022 by the Nissin Foods (Hong Kong) Charity Fund, the scholarship is designed to encourage elite athletes enrolled in the Bachelor of Health Education (Honours), Bachelor of Science (Honours) in Sports Science and Coaching, or the Postgraduate Diploma in Education programme at EdUHK. The initiative aims to support their dual career development, empowering them to become qualified health educators while continuing to strive for excellence in their athletic performance.The seven awardees for the 2025/2026 academic year include new and renewing recipients. The four new awardees are: Mr. MOK Pak Fan (triathlon), Mr. WONG Pak Yiu (triathlon), Miss HO Kin Yiu (volleyball), and Miss YAN Nuo (shuttlecock). In addition to welcoming new scholars, the Charity Fund also made the scholarship renewable to support the elite athletes throughout their study period. The three recipients of the renewed scholarship are: Mr. CHOI Kwan Lok (cycling, retired), Mr. CHEN Pak Hong (rowing), and Mr. Joseph LAU (cycling).Mr. Kiyotaka ANDO, Chairman of Nissin Foods (Hong Kong) Charity Fund, said, “Having been deeply rooted in Hong Kong for over four decades, Nissin Foods is steadfast in its mission to give back to the community. This scholarship is a direct reflection of our founder Mr. Momofuku Ando’s philosophy that ‘Eating and sports are the two axles of health.’ By supporting these talented athletes at EdUHK for the fourth year, we are not just providing financial support, we are investing in future leaders who will champion health and wellness in our society. We are proud to empower them on their dual career path, confident that they will inspire the next generation as both accomplished athletes and dedicated educators.”Expressing his profound gratitude for the long-standing partnership, Professor Chetwyn CHAN, Vice President (Research and Development) of EdUHK, said, “EdUHK is dedicated to promoting sustainable dual-career pathways for high-performance athletes. The generous Nissin Foods Scholarship for Elite Athletes allows us to support both active and retired athletes in advancing their educational pursuits, while also recognising their exceptional sporting accomplishments. I would like to extend my heartfelt congratulations to all the scholarship recipients, who demonstrated great passion, determination, and a sense of mission, and sincerely thank the Nissin Foods (Hong Kong) Charity Fund, and Mr Ando for the tremendous support and confidence in health education and the development of elite athletes.”Accomplished volleyball player Miss HO Kin Yiu, recipient of the scholarship from the Postgraduate Diploma in Education, majoring in Chinese and Physical Education, shared her heartfelt appreciation to the Charity Fund, “The support of the scholarship empowers us, as elite athlete-students, to chase our aspirations and make a meaningful influence on society. We are confident that we can help create a brighter future through the spirit of sports and education.”PhotoMr. Kiyotaka ANDO, Chairman of Nissin Foods (Hong Kong) Charity Fund (middle right), and Professor Chetwyn CHAN, Vice President (Research and Development) of EdUHK (middle left), attended the Presentation Ceremony for Nissin Foods Scholarship for Elite Athletes 2025/2026 on 27 January 2026. Five scholarship recipients attended the ceremony, including four new awardees for the 2025/2026 academic year, namely: (from left to right) Mr. MOK Pak Fan, Mr. WONG Pak Yiu, Miss HO Kin Yiu, and Miss YAN Nuo, as well as the renewed awardee - Mr. CHOI Kwan Lok. Awardees of the Nissin Foods Scholarship for Elite Athletes 2025/2026 are achieving great success in their individual disciplines. From top left: Mr. WONG Pak Yiu (triathlon), Miss HO Kin Yiu (volleyball), Mr. MOK Pak Fan (triathlon), Miss YAN Nuo (shuttlecock), Mr. CHOI Kwan Lok (cycling, retired), Mr. CHEN Pak Hong (rowing), and Mr. Joseph LAU (cycling).About Nissin Foods (Hong Kong) Charity FundThe Nissin Foods (Hong Kong) Charity Fund (“Charity Fund”) was set up in September 2020 by way of a trust deed by Nissin Foods Company Limited (Stock code: 1475). The objectives of the Charity Fund are: a) to advance education, teaching, learning, arts, science and academic research; b) to make provision for people in need; and c) to carry out works of a charitable nature that are beneficial to the Hong Kong community. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

PUTNAM, CT AND ROMEOVILLE, IL, Jan 29, 2026 - (ACN Newswire via SeaPRwire.com) - Formerra and GEON® Performance Solutions today announced an agreement that designates Formerra as the preferred distributor of Foster®, LLC medical compounds in Europe. This adds to Formerra's current distribution of these materials in North and South America, enabling Formerra to now support customers who need the same product in all regions.Following GEON's January 2025 acquisition of Foster, the agreement builds on Formerra's long-standing, global partnership with GEON for flexible and rigid PVC and filled polypropylene materials."Bringing Foster's medical-grade portfolio to Europe strengthens our ability to support healthcare manufacturers across the region with specialized compounds and the local expertise they need to navigate complex regulatory environments," said Kelly Wessner, Vice President, Key Accounts, Formerra. "Building on the momentum of our Americas partnership, we're excited to extend these proven solutions to European customers who demand the highest standards in medical device materials."With more than 30 years in custom medical polymer compounding, Foster delivers highly engineered, top-of-the-polymer-pyramid formulations tailored to demanding requirements. The portfolio includes options such as radiopaque compounds and grades that meet USP Class VI requirements and align with ISO 10993 expectations. These materials support critical end uses across the healthcare space, including implantable products and other highly specialized applications."Extending our Foster portfolio into Europe with Formerra allows us to meet growing demand from healthcare manufacturers in one of the world's most dynamic medical device markets," said Arthur Adams, Chief Commercial Officer, GEON. "This expansion reinforces our shared commitment to supporting innovation in life-saving applications globally."Adding Foster® compounds to its European portfolio will enable Formerra to better serve customers in the healthcare space, offering not only access to highly engineered medical polymers, but also deep regulatory expertise and responsive logistics across the region.Formerra will exhibit at MD&M West in Booth 2266 in Anaheim, California, February 3-5, 2026.Key DetailsFormerra will distribute Foster® medical compounds in Europe.This agreement adds custom medical-grade compounds to Formerra's existing global access to GEON® PVC and filled PP materials.About FormerraFormerra is a preeminent distributor of engineered materials, connecting the world's leading polymer producers with thousands of OEMs and brand owners across healthcare, consumer, industrial, and mobility markets. Powered by technical and commercial expertise, it brings a distinctive combination of portfolio depth, supply chain strength, industry knowledge, service, leading e-commerce capabilities, and ingenuity. The experienced Formerra team helps customers across multiple industries to design, select, process, and develop products in new and better ways - driving improved performance, productivity, reliability, and sustainability. To learn more, visit www.formerra.com.About GEON Performance SolutionsGEON® Performance Solutions unlocks the power of polymers for the future. From biomedical materials from our medical division, Foster, LLC, to building materials, automotive, connectivity, and appliances, customers in these markets rely on the portfolio of compounding solutions, highly adaptable vinyl, polyolefin, engineered resin technologies, and full-service contract manufacturing that we deliver. In every formulation, collaboration, and challenge we're shaping the brilliance of tomorrow and providing a formidable advantage by engineering what's possible. Geon has approximately 1,200 global associates and 15 world-class manufacturing plants with headquarters in Westlake, Ohio. Learn more at www.geon.com. Geon is a portfolio company of SK Capital Partners.Media ContactJackie MorrisMarketing Communications Manager, Formerrajackie.morris@formerra.com+1 630-972-3144SOURCE: Formerra Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, January 30, 2026 - (ACN Newswire via SeaPRwire.com) – A growing number of robotics and artificial intelligence companies backed by Shoucheng Holdings Limited are set to appear at China’s 2026 CMG New Year’s Gala, reflecting the investor’s expanding footprint across the country’s emerging automation and embodied intelligence sectors.The latest company to confirm its participation is Noetix Robotics, according to recent announcements. Shoucheng Holdings led the company’s financing round in 2024 and has continued to increase its investment through subsequent rounds, making it Noetix Robotics’ largest external investor, people familiar with the matter said.Noetix Robotics’ appearance adds to a lineup that already includes other Shoucheng-backed firms. Unitree Robotics, known for its quadruped and humanoid robots, was earlier named a robot partner of the 2026 Gala, marking its third appearance on the program. Beijing Galbot Co., Ltd., which focuses on embodied artificial intelligence systems, has also been designated by China Media Group as the Gala’s embodied large-model robot.The clustering of multiple portfolio companies on the same edition of the Gala places Shoucheng Holdings among a small group of investors with broad representation on one of China’s most-watched annual broadcasts. The event, which regularly draws hundreds of millions of viewers, has increasingly been used as a platform to highlight advances in artificial intelligence, robotics and advanced manufacturing.China Media Group, the organizer of the Gala, has in recent years expanded the role of technology-focused programming, aligning with national policy priorities around intelligent manufacturing and industrial upgrading. While participation in the Gala does not directly translate into revenue, companies and investors see it as an important signal of technical maturity and policy relevance.Unitree Robotics’ repeated appearances underscore this dynamic. The company has previously used the Gala to demonstrate improvements in motion control, balance and coordination, capabilities that are critical as robots move from laboratory environments into commercial and industrial settings. Its continued inclusion suggests confidence in its engineering progress and deployment readiness.Galbot’s designation as the Gala’s embodied large-model robot reflects a broader shift in focus from mechanical performance alone to systems that integrate perception, reasoning and physical execution. Embodied artificial intelligence—where large models are combined with real-world robotic interaction—has become a priority area for Chinese research institutions and technology companies as generative AI expands beyond software applications.The addition of Noetix Robotics introduces another layer to the lineup. The company concentrates on robotic power systems and core engineering components, segments that are increasingly viewed as strategic as China seeks to reduce reliance on imported technologies and strengthen domestic supply chains. Shoucheng Holdings’ sustained backing of Noetix Robotics highlights an investment strategy that spans both complete robotic systems and foundational hardware.Shoucheng Holdings has steadily increased its exposure to robotics over the past several years, backing companies involved in full-stack robotics, embodied intelligence and critical components. Rather than focusing on a single technological approach, the firm has adopted a portfolio strategy that combines capital investment with access to application scenarios and commercialization platforms.One such platform is the Shoucheng Robot Tech Experience Store, a robotics-focused retail and demonstration network operated by the company. While not all Gala participants are Shoucheng investees, some companies, including MagicLab Robotics Technology (Wuxi) Co., Ltd., have placed products such as robotic dogs within the platform’s offline spaces for demonstrations and user engagement. MagicLab was named a strategic intelligent robotics partner for the Year of the Horse CMG New Year’s Gala earlier this year.By linking high-profile media exposure with physical demonstration and sales environments, Shoucheng Holdings aims to accelerate the transition from technology showcase to market adoption, according to people familiar with the platform’s positioning. The approach mirrors a broader trend among Chinese industrial investors to combine financial backing with scenario-based deployment.Industry analysts say the concentration of Shoucheng-backed companies on the 2026 Gala stage illustrates how China’s robotics sector is evolving from isolated prototypes toward more integrated industrial ecosystems. The presence of companies spanning full robotic platforms, embodied intelligence and core engineering components suggests increasing specialization and coordination across the value chain.As preparations for the 2026 CMG New Year’s Gala continue, robotics and artificial intelligence are expected to remain central themes. For Shoucheng Holdings, the event offers a snapshot of how its investments are converging on a national platform, reflecting a strategy that has shifted from selective bets to a broader, system-oriented approach to industrial technology.While the commercial impact of Gala exposure is difficult to quantify, market participants increasingly view the lineup as an indicator of which technologies and companies are gaining momentum within China’s rapidly changing AI and automation landscape. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, January 30, 2026 - (ACN Newswire via SeaPRwire.com) – Quam Plus International Financial Limited ("Quam Plus Financial" or the "Group") is delighted to announce the successful conclusion of the "3rd Hong Kong Capital Markets Forum 2026" held at the Grand Hyatt Hong Kong. The Group is honored to be one of the Gold Sponsors of this prestigious event. Dr. Kenneth Lam, CEO of the Group, who also serves as Chairman of the Forum Organizing Committee cum Executive Deputy Chairman of The Chamber of Hong Kong Listed Companies (CHKLC), led a delegation of senior management to attend the forum. Mr. Paul Chan Mo-Po, GBM, GBS, MH, JP, Financial Secretary of the Government of HKSAR were also in attendance. Together with prominent figures from the capital markets, government, academia, and the financial sector, they engaged in in-depth discussions on further strengthening Hong Kong's economic momentum.The forum was jointly organized by Hong Kong Association of Registered Public Interest Entity Auditors Limited (PIEAA), The Chamber of Hong Kong Listed Companies (CHKLC), The Hong Kong Institute of Directors (HKIoD), and the Association of Hong Kong Capital Market Practitioners Limited (HKCMP), with strong support from key institutions including Hong Kong Exchanges and Clearing Limited (HKEX), the Securities and Futures Commission (SFC), and the Accounting and Financial Reporting Council (AFRC).As the global economy enters a new cycle of innovation and transformation, this year's forum, themed "Capturing the Next Growth Momentum” explored how Hong Kong can reinvent itself amid a rapidly changing international financial landscape, rebuild confidence, and transform challenges into powerful drivers of progress.As the globalMr. Paul Chan Mo-Po, GBM, GBS, MH, JP, served as the Guest of Honour and delivered the keynote address. He stated: "In my view, the global environment is shifting in ways that create new and favourable opportunities for Hong Kong. Our challenge is how to seize the moment and deliver tangible outcomes. More specifically, that involves supporting the country's high-quality development; matching the needs of Mainland enterprises going global and the appetite of international investors; and, at the same time, driving Hong Kong's own growth."Dr. Kenneth Lam, in his capacity as Chairman of the Forum Organizing Committee, delivered the opening remarks: "As a vital financial hub connecting China and the world, our mission is to strengthen confidence, deepen integration, and expand diverse growth engines. We must keenly identify the next wave of growth drivers and ensure that markets advance in a balanced manner between flexibility and integrity. Positioned at the core of global transformation, this forum reminds us once again that progress is never accidental—it stems from resolute choices: with innovation as our aspiration, collaboration as our bridge, and conviction as our strength, we can lead Hong Kong forward and open up new chapters."Hong Kong now stands at the heart of global change. Advancing the capital markets requires not only visionary policies and regulation but also active participation and collaboration from all sectors. This year's forum focused on two key themes—digital asset development and capital market structural reform—examining how technological innovation can coexist with trust to drive reforms that build greater market resilience.As a proud Gold Sponsor of this year's forum, Quam Plus Financial looks forward to working hand in hand with all stakeholders, including central government offices in Hong Kong and other parties, to propel Hong Kong and the region toward new achievements. Together, we aim to seize new opportunities, activate new momentum, and march toward a high-quality, sustainable financial future.About Quam Plus International Financial LimitedQuam Plus International Financial Limited (the “Company”, Stock Code: 00952.HK) is a Hong Kong based financial services group which is listed on the Main Board of the Stock Exchange of Hong Kong Limited. The Company was publicly listed in Hong Kong in 1997, it is committed to building a comprehensive, full-licensed integrated financial platform. The core businesses of the Company are brokerage business, interest income business, corporate finance business, asset management business and investments and other businesses. The Company strives to become the ideal partner for both corporate and individual investors in Hong Kong and China. The Company also offers premier one-stop financial services to its clients. The Company continued to provide capital markets services through its representative office or the wholly-owned foreign enterprise in Shenzhen, Shanghai, Shenyang, Ningbo, Beijing, Chengdu, Hangzhou and Xiamen of the PRC and through its networks of Global Alliance Partners network and Oaklins International.For further information, please contact:Quam IR LimitedMandy Lo Tel: (852) 2217-2753 Email: mandy.lo@quamgroup.comCharlie Chan Tel: (852) 2217-2504 Email: charlie.chan@quamgroup.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com